Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Curr Rev Musculoskelet Med. 2025; 18(12):611–619.
PubMed 40789979 · PMC12446177 · doi:10.1007/s12178-025-09990-7
Summarises other people's work. Generates no new data.
- Who or what was studied
- Preclinical and clinical literature on BPC-157 in musculoskeletal healing
- Design
- Scoping / narrative review
What it found
BPC-157 shows broad regenerative effects in animal models, acting on blood-vessel growth, fibroblast activity and inflammation signalling. Only three small human pilot studies exist (knee pain, interstitial cystitis, and intravenous safety), with no adverse effects reported and no large trials. The authors say BPC-157 should be treated as investigational and used with caution until well-designed trials are done.
What it doesn't show
A review generates no data of its own. 'No adverse effects' comes from very small pilot studies and cannot establish safety.
Funding and conflicts of interest
The authors declare no competing interests.
Summary written from the study's abstract and checked against PubMed on November 9, 2026. How we check studies. Educational information, not medical advice.
Related studies
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (Tewari et al., 2026)
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Mendias et al., 2026)
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi et al., 2025)
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (Lee et al., 2025)